Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enphase Energy Inc (ENPH) vs Sanofi SA (SNY) Price & Performance

Enphase Energy IncTrade

Price performance (Past 24H)

Key statistics

Enphase Energy Inc vs Sanofi SA — how do they compare? Enphase Energy Inc trades at $41.49 (market cap $5.59B), while Sanofi SA trades at $43.44 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 18.7× Enphase Energy Inc's market cap, and Sanofi SA pays a 5.55% dividend while Enphase Energy Inc pays none. Which is the better fit depends on your goals.

ENPHSNY
Market Cap
$5.59B$104.30B
Sector
TechnologyHealth
52-Week High
$72.33$52.34
52-Week Low
$26.12$41.33
Enterprise Value
$5.23B$124.19B
Dividend Yield
5.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enphase Energy Inc

Enphase Energy (ENPH) trades at $40.92, down 2.27% on the day, with a mixed technical picture showing a bullish moving average signal but neutral oscillators. Recent Q2 2026 earnings matched estimates but revenue declined 19.6% year-over-year, reflecting ongoing challenges in U.S. residential demand. The company is expanding its battery and commercial segments, with new product launches like the IQ Battery 10C aiming to drive recovery. Analyst consensus is a 'Buy' with a $45.37 price target, implying potential upside from current levels.

Outlook remains cautious but opportunistic; ENPH's valuation multiples are elevated (P/E 41.88, P/S 4.25), requiring earnings normalization for sustained gains. Key risks include cyclical solar demand, interest rate sensitivity, and competitive pressures. Near-term catalysts hinge on execution in storage and international markets, with the stock offering leverage to a sector rebound if execution improves.

Sanofi SA

SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.

The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Enphase Energy Inc

Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.

Read more on ENPH

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY